Evidence map›Paper›PMID 35484650›Full record

ArticleHaematologica2022

Copy number alterations define outcome in Philadelphia chromosome-positive acute lymphoblastic leukemia.

Helena Hohtari, Niels Pallisgaard, Matti Kankainen, Pekka Ellonen, Oscar Brück, Timo Siitonen, Marjaana Säily, Marjatta Sinisalo, Marja Pyörälä, Maija Itälä-Remes and 4 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Haematologica, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Ph+ ALL in 2022: is there an optimal approach?Hematology. American Society of Hematology. Education Program · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 8 institutions in 2 countries.

Helena HohtariHematology Research Unit Helsinki, Translational Immunology Research Program, University of Helsinki and Helsinki University Hospital Comprehensive Cancer Center, Helsinki.
Niels PallisgaardDepartment of Pathology, Zealand University Hospital, Roskilde.
Matti KankainenHematology Research Unit Helsinki, Translational Immunology Research Program, University of Helsinki and Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland; Laboratory of Genetics, HUS Diagnostic Center, Hospital District of Helsinki and Uusimaa (HUS), Helsinki, Finland; Medical and Clinical Genetics, University of Helsinki, Helsinki University Hospital, Helsinki, Finland; iCAN Digital Precision Cancer Medicine Flagship, Helsinki.
Pekka EllonenInstitute for Molecular Medicine Finland, University of Helsinki, Helsinki.
Oscar BrückHematology Research Unit Helsinki, Translational Immunology Research Program, University of Helsinki and Helsinki University Hospital Comprehensive Cancer Center, Helsinki.
Timo SiitonenDivision of Hematology, Oulu University Hospital, Oulu.
Marjaana SäilyDivision of Hematology, Oulu University Hospital, Oulu.
Marjatta SinisaloDivision of Hematology, Tampere University Hospital, Tampere.
Marja PyöräläDivision of Hematology, Kuopio University Hospital, Kuopio.
Maija Itälä-RemesDivision of Hematology, Turku University Hospital, Turku.
Perttu KoskenvesaDivision of Hematology, Helsinki University Hospital Comprehensive Cancer Center, Helsinki.
Erkki ElonenDivision of Hematology, Helsinki University Hospital Comprehensive Cancer Center, Helsinki.
Satu MustjokiHematology Research Unit Helsinki, Translational Immunology Research Program, University of Helsinki and Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland; iCAN Digital Precision Cancer Medicine Flagship, Helsinki, Finland; Department of Clinical Chemistry, University of Helsinki, Helsinki.
Kimmo PorkkaHematology Research Unit Helsinki, Translational Immunology Research Program, University of Helsinki and Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland; iCAN Digital Precision Cancer Medicine Flagship, Helsinki, Finland; Division of Hematology, Helsinki University Hospital Comprehensive Cancer Center, Helsinki.
Helsinki University Hospital · FIOulu University Hospital · FIUniversity of Helsinki · FIFinland University · FIKuopio University Hospital · FITampere University Hospital · FITurku University Hospital · FIZealand University Hospital · DK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Philadelphia ChromosomePrecursor Cell Lymphoblastic Leukemia-LymphomaDNA Copy Number VariationsHumans

Identifiers

PMID35484650
PMCPMC9335102
OpenAlexW4225132311

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.